KR101597338B1 - 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법 - Google Patents

5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법 Download PDF

Info

Publication number
KR101597338B1
KR101597338B1 KR1020127008653A KR20127008653A KR101597338B1 KR 101597338 B1 KR101597338 B1 KR 101597338B1 KR 1020127008653 A KR1020127008653 A KR 1020127008653A KR 20127008653 A KR20127008653 A KR 20127008653A KR 101597338 B1 KR101597338 B1 KR 101597338B1
Authority
KR
South Korea
Prior art keywords
chlorobenzoyl
amino
triazole
acid
dichlorobenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127008653A
Other languages
English (en)
Korean (ko)
Other versions
KR20120092587A (ko
Inventor
라시다 에이 카말리
Original Assignee
탁티칼 떼라페우틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43648255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101597338(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 탁티칼 떼라페우틱스 인크. filed Critical 탁티칼 떼라페우틱스 인크.
Publication of KR20120092587A publication Critical patent/KR20120092587A/ko
Application granted granted Critical
Publication of KR101597338B1 publication Critical patent/KR101597338B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020127008653A 2009-09-04 2010-09-03 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법 Active KR101597338B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58444809A 2009-09-04 2009-09-04
US12/584,448 2009-09-04
US12/807,415 2010-09-03
US12/807,415 US8377973B2 (en) 2009-09-04 2010-09-03 Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

Publications (2)

Publication Number Publication Date
KR20120092587A KR20120092587A (ko) 2012-08-21
KR101597338B1 true KR101597338B1 (ko) 2016-02-24

Family

ID=43648255

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008653A Active KR101597338B1 (ko) 2009-09-04 2010-09-03 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법

Country Status (19)

Country Link
US (1) US8377973B2 (enExample)
EP (2) EP2963023B1 (enExample)
JP (4) JP2013503861A (enExample)
KR (1) KR101597338B1 (enExample)
CN (2) CN102595904B (enExample)
AP (1) AP3345A (enExample)
AU (1) AU2010290049B2 (enExample)
BR (1) BR112012004539A2 (enExample)
CA (1) CA2772075C (enExample)
CL (1) CL2012000582A1 (enExample)
HK (1) HK1212983A1 (enExample)
IL (1) IL218430A0 (enExample)
MX (2) MX2012002730A (enExample)
MY (1) MY159430A (enExample)
NZ (2) NZ598482A (enExample)
PH (1) PH12015502088A1 (enExample)
RU (1) RU2594155C2 (enExample)
SG (1) SG178413A1 (enExample)
WO (1) WO2011028288A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018016795A1 (ko) * 2016-07-18 2018-01-25 일동제약주식회사 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US10378059B2 (en) * 2013-08-02 2019-08-13 Tactical Therapeutics, Inc. Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
CN112083109B (zh) * 2019-07-08 2021-05-25 广东银珠医药科技有限公司 羧胺三唑杂质及其制备方法和检测方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
CN112358451B (zh) * 2021-01-11 2021-04-13 广东银珠医药科技有限公司 羧胺三唑的合成方法
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN113620892B (zh) * 2021-10-12 2022-02-22 广东银珠医药科技有限公司 羧胺三唑单晶、制备方法及其组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189640A1 (en) * 2005-02-22 2006-08-24 Karmali Rashida A Method of increasing drug oral bioavailability and compositions of less toxic orotate salts

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2415740C2 (de) * 1974-04-01 1983-12-01 Servomed Arznei GmbH & Co Pharma KG, 8000 München Verwendung von Orotsäure bei der analgetischen Behandlung mit Dextropropoxyphen, Natriumsalicylat oder Metamizol
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
US4847257A (en) * 1987-08-20 1989-07-11 Merck & Co., Inc. 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents
JPH0356417A (ja) * 1989-05-08 1991-03-12 Merck & Co Inc 抗転移剤として有用な５―アミノ又は置換アミノ１，２，３―トリアゾール類
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5359078A (en) 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
WO1997003668A1 (en) * 1995-07-21 1997-02-06 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
TW526195B (en) * 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
MXPA06013540A (es) * 2004-05-25 2007-01-26 Astrazeneca Ab Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
MX2010002938A (es) * 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
US20150323994A1 (en) * 2014-05-07 2015-11-12 Immersion Corporation Dynamic haptic effect modification
JP2017150532A (ja) * 2016-02-23 2017-08-31 Ntn株式会社 回転伝達装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189640A1 (en) * 2005-02-22 2006-08-24 Karmali Rashida A Method of increasing drug oral bioavailability and compositions of less toxic orotate salts

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018016795A1 (ko) * 2016-07-18 2018-01-25 일동제약주식회사 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
EP2963023B1 (en) 2018-04-18
BR112012004539A2 (pt) 2020-09-15
NZ624636A (en) 2014-06-27
US20110060142A1 (en) 2011-03-10
CA2772075C (en) 2017-02-28
NZ598482A (en) 2014-05-30
EP2473051A1 (en) 2012-07-11
JP2020105178A (ja) 2020-07-09
EP2473051A4 (en) 2013-03-13
AP2012006187A0 (en) 2012-04-30
WO2011028288A1 (en) 2011-03-10
JP2017203038A (ja) 2017-11-16
IL218430A0 (en) 2012-04-30
RU2012111454A (ru) 2013-10-10
HK1212983A1 (zh) 2016-06-24
MX355198B (es) 2018-04-06
MY159430A (en) 2017-01-13
CN102595904B (zh) 2016-08-03
JP2013503861A (ja) 2013-02-04
CN104817507A (zh) 2015-08-05
PH12015502088B1 (en) 2017-03-22
AP3345A (en) 2015-07-31
AU2010290049B2 (en) 2013-09-19
CA2772075A1 (en) 2011-03-10
PH12015502088A1 (en) 2017-03-22
AU2010290049A1 (en) 2012-03-29
KR20120092587A (ko) 2012-08-21
CN102595904A (zh) 2012-07-18
US8377973B2 (en) 2013-02-19
EP2473051B1 (en) 2016-02-10
MX2012002730A (es) 2012-07-20
CL2012000582A1 (es) 2012-09-07
JP2016026213A (ja) 2016-02-12
EP2963023A1 (en) 2016-01-06
SG178413A1 (en) 2012-03-29
RU2594155C2 (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
KR101597338B1 (ko) 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법
EP2773378B1 (en) Prodrugs of non-steroid anti-inflammatory agents (nsaids)
JP2022125284A (ja) ３－ヒドロキシ－４，５－ビス－ベンジルオキシ－６－ベンジルオキシメチル－２－フェニル－２－オキソ－２λ５－［１，２］オキサホスフィナンの結晶多形体
US8912223B2 (en) Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
KR100979077B1 (ko) 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물
CN115702902B (zh) 一种阿霉素前药抗肿瘤制剂
US20190298845A1 (en) Conjugate of dezocine and polyethylene glycol
HK1214824B (en) Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
HK1214824A1 (en) Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
HK1170631B (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
HK1170631A (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
WO2022087763A1 (zh) 含有索拉非尼游离碱和5-氟尿嘧啶的共晶体、药物组合物及其用途
EP2991682B1 (en) Prodrugs of naproxen and diclofenac
JP2007531736A (ja) ヌクレオシド誘導体およびそれらの治療用途
EP1412337A1 (en) Azole compounds as anti-fungal agents
JP2003514803A (ja) 結直腸ガンの発達を防止するための４−（４’−ヒドロキシフェニル）アミノ−６，７−ジメトキシキナゾリン
JPH10338690A (ja) アスコルビン酸誘導体およびその用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120403

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130905

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150223

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150915

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20150915

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20150421

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120405

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20151117

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20151016

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150915

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20150421

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20120405

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160218

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160219

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190208

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190208

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200212

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20200212

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210208

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230202

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20250204

Start annual number: 10

End annual number: 10